Ropeginterferon alfa-2b clinical trials

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

This study is testing a new medicine called Ropeginterferon Alfa-2b for a blood condition known as Essential Thrombocythemia (ET). It compares this new medicine with an existing one, Anagrelide, to see which is safer and works better for patients who haven't responded well to another treatment, Hydroxyurea.